Cargando…

A type III effectiveness-implementation hybrid evaluation of a multicomponent patient navigation strategy for advanced-stage Kaposi’s sarcoma: protocol

BACKGROUND: For people with advanced-stage Kaposi’s sarcoma (KS), a common HIV-associated malignancy in sub-Saharan Africa, mortality is estimated to be 45% within 2 years after KS diagnosis, despite increasingly wide-spread availability of antiretroviral therapy and chemotherapy. For advanced-stage...

Descripción completa

Detalles Bibliográficos
Autores principales: Collier, Sigrid, Semeere, Aggrey, Byakwaga, Helen, Laker-Oketta, Miriam, Chemtai, Linda, Wagner, Anjuli D., Bassett, Ingrid V., Wools-Kaloustian, Kara, Maurer, Toby, Martin, Jeffrey, Kiprono, Samson, Freeman, Esther E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9102240/
https://www.ncbi.nlm.nih.gov/pubmed/35562783
http://dx.doi.org/10.1186/s43058-022-00281-7
_version_ 1784707282516312064
author Collier, Sigrid
Semeere, Aggrey
Byakwaga, Helen
Laker-Oketta, Miriam
Chemtai, Linda
Wagner, Anjuli D.
Bassett, Ingrid V.
Wools-Kaloustian, Kara
Maurer, Toby
Martin, Jeffrey
Kiprono, Samson
Freeman, Esther E.
author_facet Collier, Sigrid
Semeere, Aggrey
Byakwaga, Helen
Laker-Oketta, Miriam
Chemtai, Linda
Wagner, Anjuli D.
Bassett, Ingrid V.
Wools-Kaloustian, Kara
Maurer, Toby
Martin, Jeffrey
Kiprono, Samson
Freeman, Esther E.
author_sort Collier, Sigrid
collection PubMed
description BACKGROUND: For people with advanced-stage Kaposi’s sarcoma (KS), a common HIV-associated malignancy in sub-Saharan Africa, mortality is estimated to be 45% within 2 years after KS diagnosis, despite increasingly wide-spread availability of antiretroviral therapy and chemotherapy. For advanced-stage KS, chemotherapy in addition to antiretroviral therapy improves outcomes and saves lives, but currently, only ~50% of people with KS in western Kenya who have an indication for chemotherapy actually receive it. This protocol describes the evaluation of a multicomponent patient navigation strategy that addresses common barriers to service penetration of and fidelity to evidence-based chemotherapy among people with advanced-stage KS in Kenya. METHODS: This is a hybrid type III effectiveness-implementation study using a non-randomized, pre- post-design nested within a longitudinal cohort. We will compare the delivery of evidence-based chemotherapy for advanced-stage KS during the period before (2016–2020) to the period after (2021–2024), the rollout of a multicomponent patient navigation strategy. The multicomponent patient navigation strategy was developed in a systematic process to address key determinants of service penetration of and fidelity to chemotherapy in western Kenya and includes (1) physical navigation and care coordination, (2) video-based education, (3) travel stipend, (4) health insurance enrollment assistance, (5) health insurance stipend, and (6) peer mentorship. We will compare the pre-navigation period to the post-navigation period to assess the impact of this multicomponent patient navigation strategy on (1) implementation outcomes: service penetration (chemotherapy initiation) and fidelity (chemotherapy completion) and (2) service and client outcomes: timeliness of cancer care, mortality, quality of life, stigma, and social support. We will also describe the implementation process and the determinants of implementation success for the multicomponent patient navigation strategy. DISCUSSION: This study addresses an urgent need for effective implementation strategies to improve the initiation and completion of evidence-based chemotherapy in advanced-stage KS. By using a clearly specified, theory-based implementation strategy and validated frameworks, this study will contribute to a more comprehensive understanding of how to improve cancer treatment in advanced-stage KS. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s43058-022-00281-7.
format Online
Article
Text
id pubmed-9102240
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-91022402022-05-14 A type III effectiveness-implementation hybrid evaluation of a multicomponent patient navigation strategy for advanced-stage Kaposi’s sarcoma: protocol Collier, Sigrid Semeere, Aggrey Byakwaga, Helen Laker-Oketta, Miriam Chemtai, Linda Wagner, Anjuli D. Bassett, Ingrid V. Wools-Kaloustian, Kara Maurer, Toby Martin, Jeffrey Kiprono, Samson Freeman, Esther E. Implement Sci Commun Study Protocol BACKGROUND: For people with advanced-stage Kaposi’s sarcoma (KS), a common HIV-associated malignancy in sub-Saharan Africa, mortality is estimated to be 45% within 2 years after KS diagnosis, despite increasingly wide-spread availability of antiretroviral therapy and chemotherapy. For advanced-stage KS, chemotherapy in addition to antiretroviral therapy improves outcomes and saves lives, but currently, only ~50% of people with KS in western Kenya who have an indication for chemotherapy actually receive it. This protocol describes the evaluation of a multicomponent patient navigation strategy that addresses common barriers to service penetration of and fidelity to evidence-based chemotherapy among people with advanced-stage KS in Kenya. METHODS: This is a hybrid type III effectiveness-implementation study using a non-randomized, pre- post-design nested within a longitudinal cohort. We will compare the delivery of evidence-based chemotherapy for advanced-stage KS during the period before (2016–2020) to the period after (2021–2024), the rollout of a multicomponent patient navigation strategy. The multicomponent patient navigation strategy was developed in a systematic process to address key determinants of service penetration of and fidelity to chemotherapy in western Kenya and includes (1) physical navigation and care coordination, (2) video-based education, (3) travel stipend, (4) health insurance enrollment assistance, (5) health insurance stipend, and (6) peer mentorship. We will compare the pre-navigation period to the post-navigation period to assess the impact of this multicomponent patient navigation strategy on (1) implementation outcomes: service penetration (chemotherapy initiation) and fidelity (chemotherapy completion) and (2) service and client outcomes: timeliness of cancer care, mortality, quality of life, stigma, and social support. We will also describe the implementation process and the determinants of implementation success for the multicomponent patient navigation strategy. DISCUSSION: This study addresses an urgent need for effective implementation strategies to improve the initiation and completion of evidence-based chemotherapy in advanced-stage KS. By using a clearly specified, theory-based implementation strategy and validated frameworks, this study will contribute to a more comprehensive understanding of how to improve cancer treatment in advanced-stage KS. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s43058-022-00281-7. BioMed Central 2022-05-13 /pmc/articles/PMC9102240/ /pubmed/35562783 http://dx.doi.org/10.1186/s43058-022-00281-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Study Protocol
Collier, Sigrid
Semeere, Aggrey
Byakwaga, Helen
Laker-Oketta, Miriam
Chemtai, Linda
Wagner, Anjuli D.
Bassett, Ingrid V.
Wools-Kaloustian, Kara
Maurer, Toby
Martin, Jeffrey
Kiprono, Samson
Freeman, Esther E.
A type III effectiveness-implementation hybrid evaluation of a multicomponent patient navigation strategy for advanced-stage Kaposi’s sarcoma: protocol
title A type III effectiveness-implementation hybrid evaluation of a multicomponent patient navigation strategy for advanced-stage Kaposi’s sarcoma: protocol
title_full A type III effectiveness-implementation hybrid evaluation of a multicomponent patient navigation strategy for advanced-stage Kaposi’s sarcoma: protocol
title_fullStr A type III effectiveness-implementation hybrid evaluation of a multicomponent patient navigation strategy for advanced-stage Kaposi’s sarcoma: protocol
title_full_unstemmed A type III effectiveness-implementation hybrid evaluation of a multicomponent patient navigation strategy for advanced-stage Kaposi’s sarcoma: protocol
title_short A type III effectiveness-implementation hybrid evaluation of a multicomponent patient navigation strategy for advanced-stage Kaposi’s sarcoma: protocol
title_sort type iii effectiveness-implementation hybrid evaluation of a multicomponent patient navigation strategy for advanced-stage kaposi’s sarcoma: protocol
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9102240/
https://www.ncbi.nlm.nih.gov/pubmed/35562783
http://dx.doi.org/10.1186/s43058-022-00281-7
work_keys_str_mv AT colliersigrid atypeiiieffectivenessimplementationhybridevaluationofamulticomponentpatientnavigationstrategyforadvancedstagekaposissarcomaprotocol
AT semeereaggrey atypeiiieffectivenessimplementationhybridevaluationofamulticomponentpatientnavigationstrategyforadvancedstagekaposissarcomaprotocol
AT byakwagahelen atypeiiieffectivenessimplementationhybridevaluationofamulticomponentpatientnavigationstrategyforadvancedstagekaposissarcomaprotocol
AT lakerokettamiriam atypeiiieffectivenessimplementationhybridevaluationofamulticomponentpatientnavigationstrategyforadvancedstagekaposissarcomaprotocol
AT chemtailinda atypeiiieffectivenessimplementationhybridevaluationofamulticomponentpatientnavigationstrategyforadvancedstagekaposissarcomaprotocol
AT wagneranjulid atypeiiieffectivenessimplementationhybridevaluationofamulticomponentpatientnavigationstrategyforadvancedstagekaposissarcomaprotocol
AT bassettingridv atypeiiieffectivenessimplementationhybridevaluationofamulticomponentpatientnavigationstrategyforadvancedstagekaposissarcomaprotocol
AT woolskaloustiankara atypeiiieffectivenessimplementationhybridevaluationofamulticomponentpatientnavigationstrategyforadvancedstagekaposissarcomaprotocol
AT maurertoby atypeiiieffectivenessimplementationhybridevaluationofamulticomponentpatientnavigationstrategyforadvancedstagekaposissarcomaprotocol
AT martinjeffrey atypeiiieffectivenessimplementationhybridevaluationofamulticomponentpatientnavigationstrategyforadvancedstagekaposissarcomaprotocol
AT kipronosamson atypeiiieffectivenessimplementationhybridevaluationofamulticomponentpatientnavigationstrategyforadvancedstagekaposissarcomaprotocol
AT freemanesthere atypeiiieffectivenessimplementationhybridevaluationofamulticomponentpatientnavigationstrategyforadvancedstagekaposissarcomaprotocol
AT colliersigrid typeiiieffectivenessimplementationhybridevaluationofamulticomponentpatientnavigationstrategyforadvancedstagekaposissarcomaprotocol
AT semeereaggrey typeiiieffectivenessimplementationhybridevaluationofamulticomponentpatientnavigationstrategyforadvancedstagekaposissarcomaprotocol
AT byakwagahelen typeiiieffectivenessimplementationhybridevaluationofamulticomponentpatientnavigationstrategyforadvancedstagekaposissarcomaprotocol
AT lakerokettamiriam typeiiieffectivenessimplementationhybridevaluationofamulticomponentpatientnavigationstrategyforadvancedstagekaposissarcomaprotocol
AT chemtailinda typeiiieffectivenessimplementationhybridevaluationofamulticomponentpatientnavigationstrategyforadvancedstagekaposissarcomaprotocol
AT wagneranjulid typeiiieffectivenessimplementationhybridevaluationofamulticomponentpatientnavigationstrategyforadvancedstagekaposissarcomaprotocol
AT bassettingridv typeiiieffectivenessimplementationhybridevaluationofamulticomponentpatientnavigationstrategyforadvancedstagekaposissarcomaprotocol
AT woolskaloustiankara typeiiieffectivenessimplementationhybridevaluationofamulticomponentpatientnavigationstrategyforadvancedstagekaposissarcomaprotocol
AT maurertoby typeiiieffectivenessimplementationhybridevaluationofamulticomponentpatientnavigationstrategyforadvancedstagekaposissarcomaprotocol
AT martinjeffrey typeiiieffectivenessimplementationhybridevaluationofamulticomponentpatientnavigationstrategyforadvancedstagekaposissarcomaprotocol
AT kipronosamson typeiiieffectivenessimplementationhybridevaluationofamulticomponentpatientnavigationstrategyforadvancedstagekaposissarcomaprotocol
AT freemanesthere typeiiieffectivenessimplementationhybridevaluationofamulticomponentpatientnavigationstrategyforadvancedstagekaposissarcomaprotocol